Emend - (EQ 150, 115 mg BASE/VIAL; Powder, Intravenous)

Generic Name	Fosaprepitant dimeglumine	**Innovator**	Merck
Dosage	EQ 150, 115 mg BASE/VIAL; Powder, Intravenous	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of high or moderate emetogenic cancer.		
Complexities	Yes		

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Emend - (125MG/Kit ; For Suspension)

Generic Name	Fosaprepitant dimeglumine	**Innovator**	MSD
Dosage	125MG/Kit ; For Suspension	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	EMEND ® is a substance P/neurokinin 1 (NK1) receptor antagonist. EMEND for oral suspension is indicated • in combination with other antiemetic agents, in patients 6 months of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.